No Data
Hualan Vaccine: 2024 performance forecast
Hualan Vaccine (301207.SZ): The net income for the fiscal year 2024 is expected to decrease by 70.93% to 76.74%.
On January 16, Gelonghui reported that Hualan Vaccine (301207.SZ) announced its performance forecast for 2024. The net income attributed to shareholders of the listed company is expected to be between 0.2 billion yuan and 0.25 billion yuan, a decrease of 76.74%-70.93% compared to the same period last year; the net income excluding non-recurring gains and losses is expected to be between 0.11 billion yuan and 0.16 billion yuan, a decrease of 85.49%-78.89% compared to the same period last year. To improve the accessibility of flu vaccines, enhance product market competitiveness and market share, reduce the economic burden on the public and the government, and fulfill corporate social responsibility, the company will combine market conditions.
Does Hualan Biological Vaccine (SZSE:301207) Have A Healthy Balance Sheet?
Luan Vaccine (301207.SZ) CFO Lu Chengyu has resigned.
Hualan Vaccine (301207.SZ) announced that the Board of Directors recently received a report from the company's Board of Directors Secretary and Chief Financial Officer, Lu...
Hualan Biological Vaccine's (SZSE:301207) Shareholders Have More To Worry About Than Only Soft Earnings
Hualan Vaccine: Report for the third quarter of 2024
